To read the full story, subscribe or sign in.

Halozyme Sinks as FDA Asks for HyQ Long-Term-Use Data

April 17, 2012

Shares of Halozyme Therapeutics Inc. fell 24 percent Monday after the biotech and partner Baxter International Inc. revealed the FDA needs more information to complete its review of subcutaneous immunoglobulin product HyQ.

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for April 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 22, 2025.

Three lines of white dice with people icons, red dice with scissors icons

Biopharma restructurings reflect strategy of short-term pain for long-term gains

BioWorld

Ongoing restructurings in the biopharma sector show common themes of cost-cutting, clinical failures and shifting strategic priorities. Companies are increasingly...

Field Medical harvests $40M for PFA system

BioWorld MedTech

Field Medical Inc. reaped $40 million in its series A fundraising via $20 million in new capital and conversion of $20 million in seed-round debt to support...

Roche cobas IMPACT: chip-based immunological multimarker assay

Roche follows other pharmas, committing $50B in US investment

BioWorld

Roche AG has become the latest pharmaceutical company to respond to the Trump administration’s threat to impose tariffs, saying it will invest $50 billion in drug...